Polycystic ovary syndrome (PCOS) is one of the most common endocrine conditions affecting women of reproductive age in the UK, with approximately 1 in 10 women affected. Weight management is a cornerstone of PCOS treatment, and Mounjaro (tirzepatide) is generating interest as a potential tool in this area.
The Link Between PCOS and Weight
Up to 80% of women with PCOS are overweight or obese. Excess weight worsens many PCOS symptoms by increasing insulin resistance, which in turn drives:
- Elevated androgen levels, contributing to acne, hirsutism, and hair thinning
- Irregular menstrual cycles and ovulatory dysfunction
- Increased risk of type 2 diabetes and metabolic syndrome
- Reduced fertility and complications during pregnancy
Even a modest weight loss of 5-10% can significantly improve these symptoms, making effective weight management treatments highly relevant for PCOS patients.
Why Tirzepatide Is of Interest
Mounjaro's dual GIP/GLP-1 mechanism addresses two key issues in PCOS: insulin resistance and excess weight. By improving insulin sensitivity and promoting significant weight loss, tirzepatide may help break the cycle that drives PCOS symptoms.
Early clinical observations and small-scale studies have reported improvements in menstrual regularity, androgen levels, and metabolic markers in women with PCOS taking GLP-1 based therapies. Dedicated PCOS trials with tirzepatide are anticipated.
Current UK Prescribing for PCOS
At present, Mounjaro is not specifically licensed for PCOS treatment in the UK. However, women with PCOS who also meet the criteria for weight management or type 2 diabetes treatment may be eligible for a prescription. NICE guidelines recommend lifestyle interventions as first-line treatment for PCOS-related weight management, with pharmacotherapy considered when these are insufficient.
What to Consider
If you have PCOS and are interested in Mounjaro, consider discussing the following with your GP or gynaecologist:
- Your current BMI, insulin resistance status, and metabolic profile
- Whether you are planning pregnancy (Mounjaro must be stopped at least 2 months before conception)
- How tirzepatide fits alongside other PCOS treatments such as metformin or hormonal contraceptives
- Monitoring plans for menstrual regularity and hormonal levels
Looking Ahead
The intersection of GLP-1 therapies and PCOS management is an active area of research. While we await dedicated trial data, many UK clinicians are cautiously optimistic about the potential of Mounjaro to improve quality of life for women living with PCOS. MedsLens will continue to track developments and pricing for UK patients.